The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibodys latest Press releases

To the archive

2019-09-23

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today...[read more]

2019-09-20

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET...[read more]

2019-08-23

Interim Report – January to June 2019...[read more]